In an eight-week study of six monkeys per group, the Activin E antibody shifted loss toward fat versus 77% on semaglutide alone. Human trials are planned for 2027.
Recap by typeshit. Full story at Longevity.Technology.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
The Independent Medical Alliance doctor weighs in on what is still unknown about the long-term safety of GLP-1 drugs used by millions of Americans.
Gounder notes the policy requires no testing of finished vials or deadline for side effect reports, and public comments on the draft run through November 13.
Loading…